Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.
Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.
This activity is supported by an educational grant from Incyte Corporation.
International Ballroom South (Lobby Level)
720 S Michigan Avenue
Chicago, IL 60605
Optimizing treatment for patients with myeloproliferative neoplasms (MPNs) is challenging. There is a need for educational initiatives that provide clinicians with practical approaches that they can apply to maximize clinical benefits in patients they manage. A personalized approach to care in individual patients is key given that MPNs are heterogeneous with regard to their features, including prognosis, disease burden, symptoms, and genetic mutations; mutational driver status can substantially impact prognosis and diagnosis. Treatment goals for patients with MPNs focus on mitigating such long-term risks as vascular events and premature mortality, but also on minimizing disease burden and morbidity. This is a particularly important goal for those individuals with highly symptomatic disease.
Advances in the understanding of the pathobiology of MPNs resulted in the development of approaches that target the JAK/STAT signaling pathway, and the subsequent approval of a JAK1/JAK2 inhibitor. Novel strategies to manage MPNs remain a major focus of late-stage clinical trial evaluation. In fact, treatment paradigms promise to continue evolving in the near future in parallel with improved knowledge of how to practically apply biomarkers and manage treatment-related toxicities, and with the emergence of novel targeted compounds and combination approaches that are in various stages of clinical development.
This exciting, interactive, symposium will feature leading experts in the management of MPNs, and will assist practitioners in optimizing outcomes for their patients. The meeting will focus on methods to optimize the efficacy and safety of current management strategies, as well as new potentially practice-changing approaches that may further advance the field, which are currently being evaluated in clinical trials.
This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of hematological disorders. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with hematological disorders will be invited to participate.
Upon completion of this activity, participants will be able to:
Ruben A. Mesa, MD, FACP
Chair, Division of Hematology & Medical Oncology
Deputy Director, Mayo Clinic Cancer Center
Professor of Medicine
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018